Back

Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis

2020-04-03 intensive care and critical care medicine Title + abstract only
View on medRxiv
Show abstract

PurposeCoronaviruses may activate dysregulated host immune responses. As exploratory studies have suggested that interleukin-6 (IL-6) levels are elevated in cases of complicated COVID-19 and that the anti-IL-6 biologic tocilizumab may be beneficial, we undertook a systematic review and meta-analysis to assess the evidence in this field. MethodsWe systematically searched MEDLINE and EMBASE for studies investigating the immunological response in COVID-19 or its treatment with tocilizumab; additio...

Predicted journal destinations